Conformis, Inc. (NASDAQ:CFMS – Get Rating) – Equities research analysts at Oppenheimer upped their FY2023 EPS estimates for Conformis in a research note issued on Thursday, March 2nd. Oppenheimer analyst S. Lichtman now anticipates that the medical instruments supplier will earn ($5.57) per share for the year, up from their prior forecast of ($5.85). Oppenheimer has a “Outperform” rating and a $8.00 price objective on the stock. The consensus estimate for Conformis’ current full-year earnings is ($5.29) per share.
Separately, StockNews.com assumed coverage on shares of Conformis in a research note on Tuesday, November 29th. They issued a “hold” rating on the stock.
Conformis Price Performance
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the business. Wasatch Advisors Inc. boosted its stake in Conformis by 9.7% during the 1st quarter. Wasatch Advisors Inc. now owns 20,030,298 shares of the medical instruments supplier’s stock valued at $12,495,000 after purchasing an additional 1,778,054 shares in the last quarter. State Street Corp boosted its position in Conformis by 4.2% during the first quarter. State Street Corp now owns 3,368,168 shares of the medical instruments supplier’s stock worth $2,101,000 after purchasing an additional 136,641 shares during the period. Renaissance Technologies LLC boosted its position in Conformis by 4.1% during the third quarter. Renaissance Technologies LLC now owns 4,763,691 shares of the medical instruments supplier’s stock worth $911,000 after purchasing an additional 188,200 shares during the period. Millennium Management LLC acquired a new position in shares of Conformis during the second quarter worth approximately $160,000. Finally, Dimensional Fund Advisors LP acquired a new position in shares of Conformis during the fourth quarter worth approximately $91,000.
ConforMIS, Inc is a medical technology company, which engages in the development, manufacture, and sale of joint replacement implants. It operates through the following geographical segments: United States, Germany, and Rest of the World. The firm’s products include iUni, iDuo, iTotal CR, and iTotal.
- Get a free copy of the StockNews.com research report on Conformis (CFMS)
- MarketBeat Week in Review – 2/27 – 3/3
- The 3 Most Upgraded Stocks Are Reversing
- How to Find Blue Chip Dividend Stocks
- Zscaler, Inc Plummets, Is It Time To Buy The Dip?
- What is a Good Dividend Yield? How to Decide
Receive News & Ratings for Conformis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conformis and related companies with MarketBeat.com's FREE daily email newsletter.